BRPI0610187B8 - tablete dispersável ou um solvato ou sal farmaceuticamente aceitável do mesmo, e excipientes farmaceuticamente aceitáveis, processo para a preparação dos mesmos, e uso de composto ou de um sal ou solvato farmaceuticamente aceitável do mesmo - Google Patents

tablete dispersável ou um solvato ou sal farmaceuticamente aceitável do mesmo, e excipientes farmaceuticamente aceitáveis, processo para a preparação dos mesmos, e uso de composto ou de um sal ou solvato farmaceuticamente aceitável do mesmo

Info

Publication number
BRPI0610187B8
BRPI0610187B8 BRPI0610187A BRPI0610187A BRPI0610187B8 BR PI0610187 B8 BRPI0610187 B8 BR PI0610187B8 BR PI0610187 A BRPI0610187 A BR PI0610187A BR PI0610187 A BRPI0610187 A BR PI0610187A BR PI0610187 B8 BRPI0610187 B8 BR PI0610187B8
Authority
BR
Brazil
Prior art keywords
pharmaceutically acceptable
solvate
acceptable salt
compound
preparation
Prior art date
Application number
BRPI0610187A
Other languages
English (en)
Inventor
Holman Lovelace
Trenktrog Timm
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37431647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0610187(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of BRPI0610187A2 publication Critical patent/BRPI0610187A2/pt
Publication of BRPI0610187B1 publication Critical patent/BRPI0610187B1/pt
Publication of BRPI0610187B8 publication Critical patent/BRPI0610187B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

tablete dispersável ou um solvato ou sal farmaceuticamente aceitável do mesmo, e excipientes farmaceuticamente aceitáveis, processo para a preparação dos mesmos, e, uso de composto ou de um sal ou solvato farmaceuticamente aceitável do mesmo a invenção refere-se aos tabletes dispersáveis compreendendo o composto 4-tere-butil-n- [6-(2-hidróxi-etóxi)-5 -(2-metóxi-fenóxi)-2-(pirimidin-2-il-pirimidin-4-il]-benzeno-sulfonamida.
BRPI0610187A 2005-05-17 2006-05-15 tablete dispersável ou um solvato ou sal farmaceuticamente aceitável do mesmo, e excipientes farmaceuticamente aceitáveis, processo para a preparação dos mesmos, e uso de composto ou de um sal ou solvato farmaceuticamente aceitável do mesmo BRPI0610187B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2005/005367 2005-05-17
EP2005005367 2005-05-17
PCT/IB2006/051519 WO2006123285A2 (en) 2005-05-17 2006-05-15 Dispersible bosertan tablet

Publications (3)

Publication Number Publication Date
BRPI0610187A2 BRPI0610187A2 (pt) 2010-06-01
BRPI0610187B1 BRPI0610187B1 (pt) 2020-03-03
BRPI0610187B8 true BRPI0610187B8 (pt) 2021-05-25

Family

ID=37431647

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0610187A BRPI0610187B8 (pt) 2005-05-17 2006-05-15 tablete dispersável ou um solvato ou sal farmaceuticamente aceitável do mesmo, e excipientes farmaceuticamente aceitáveis, processo para a preparação dos mesmos, e uso de composto ou de um sal ou solvato farmaceuticamente aceitável do mesmo

Country Status (23)

Country Link
US (3) US7959945B2 (pt)
EP (1) EP1883397B1 (pt)
JP (1) JP4219399B2 (pt)
KR (2) KR20100093105A (pt)
CN (1) CN101175484B (pt)
AT (1) ATE451914T1 (pt)
AU (1) AU2006248593B2 (pt)
BR (1) BRPI0610187B8 (pt)
CA (1) CA2607098C (pt)
CY (1) CY1110610T1 (pt)
DE (1) DE602006011150D1 (pt)
DK (1) DK1883397T3 (pt)
ES (1) ES2336943T3 (pt)
IL (1) IL187383A (pt)
MX (1) MX2007014454A (pt)
NO (1) NO339781B1 (pt)
NZ (1) NZ564167A (pt)
PL (1) PL1883397T3 (pt)
PT (1) PT1883397E (pt)
RU (2) RU2404774C2 (pt)
SI (1) SI1883397T1 (pt)
WO (1) WO2006123285A2 (pt)
ZA (1) ZA200710903B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE451914T1 (de) 2005-05-17 2010-01-15 Actelion Pharmaceuticals Ltd Dispergierbare bosertan-tablette
US8664390B2 (en) 2007-06-29 2014-03-04 Generics (Uk) Limited Process for the introduction of hydroxyethoxy side chain in bosentan
CA2712860C (en) 2008-02-08 2014-11-18 Abhay Gaitonde Process for preparing bosentan
CA2741928A1 (en) 2008-11-03 2010-06-03 Generics [Uk] Limited Hplc method for the analysis of bosentan and related substances and use of these substances as reference standards and markers
MY162940A (en) 2009-08-19 2017-07-31 Eisai R&D Man Co Ltd Quinoline derivative-containing pharmaceutical composition
JP5850576B2 (ja) * 2010-07-06 2016-02-03 富士化学工業株式会社 ボセンタン固体分散体
CN102114005B (zh) * 2010-12-06 2012-12-12 武汉武药科技有限公司 一种波生坦胶囊及其制备方法
EP2696857A1 (en) 2011-04-11 2014-02-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical composition comprising bosentan
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
JP2015503555A (ja) 2012-05-11 2015-02-02 ハナル・バイオファーマ・カンパニー・リミテッド ボセンタン制御放出性経口製剤
KR101451327B1 (ko) * 2013-01-08 2014-11-03 안국약품 주식회사 보센탄의 제어방출성 다층 정제 및 그 제조방법
RU2559424C1 (ru) * 2014-06-18 2015-08-10 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения Российской Федерации (ФГБУ "РКНПК" Минздрава России) Способ подбора лекарственной терапии больным с идиопатической легочной гипертензией
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
LT3263106T (lt) * 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
CN104840965B (zh) * 2015-05-05 2018-05-08 重庆华邦制药有限公司 波生坦的制剂及其稳定剂
KR20160141045A (ko) 2015-05-27 2016-12-08 한올바이오파마주식회사 보센탄을 함유한 약학적 조성물
MX373231B (es) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
US12220398B2 (en) 2015-08-20 2025-02-11 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
CN108703956A (zh) * 2018-08-21 2018-10-26 天津双硕医药科技有限公司 一种含有波生坦的固体药物组合物
US11969424B2 (en) 2019-12-16 2024-04-30 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
TR2021019265A2 (tr) * 2021-12-07 2023-06-21 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Bosentan farmasötik bileşimleri.
WO2023128902A1 (en) * 2021-12-30 2023-07-06 Pharmactive Ilac Sanayi Ve Ticaret A.S. Pharmaceutical compositions comprising bosentan and relevant excipients
US20250064799A1 (en) 2021-12-31 2025-02-27 Tenax Therapeutics, Inc. Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction
CN114533738A (zh) * 2022-02-19 2022-05-27 苏州海景医药科技有限公司 一种波生坦固体药物组合物及其制备方法
WO2026007874A1 (zh) * 2024-07-02 2026-01-08 亚宝药业集团股份有限公司 一种波生坦微片

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
CA2355411A1 (en) * 2000-08-18 2002-02-18 Queen's University At Kingston Combination therapy using sympathetic nervous system antagonists and endothelin antagonists
JP2005529933A (ja) * 2002-05-31 2005-10-06 シェーリング　コーポレイション キサンチンホスホジエステラーゼｖインヒビター多形体
US20040102361A1 (en) * 2002-11-27 2004-05-27 Frederic Bodin Pharmaceutical composition for the treatment of pulmonary arterial hypertension
KR100604034B1 (ko) 2003-10-08 2006-07-24 주식회사유한양행 암로디핀 유리염기를 함유한 구강 속붕해정 및 그의 조성물
ATE451914T1 (de) * 2005-05-17 2010-01-15 Actelion Pharmaceuticals Ltd Dispergierbare bosertan-tablette

Also Published As

Publication number Publication date
US20110245281A1 (en) 2011-10-06
US20080193528A1 (en) 2008-08-14
IL187383A0 (en) 2008-02-09
MX2007014454A (es) 2008-02-07
PL1883397T3 (pl) 2010-05-31
ATE451914T1 (de) 2010-01-15
DE602006011150D1 (de) 2010-01-28
NO339781B1 (no) 2017-01-30
US20130023547A1 (en) 2013-01-24
JP2008540512A (ja) 2008-11-20
US8309126B2 (en) 2012-11-13
HK1120212A1 (en) 2009-03-27
NZ564167A (en) 2009-12-24
RU2007146395A (ru) 2009-06-27
IL187383A (en) 2011-09-27
PT1883397E (pt) 2010-02-23
AU2006248593A1 (en) 2006-11-23
WO2006123285A2 (en) 2006-11-23
US7959945B2 (en) 2011-06-14
KR20100093105A (ko) 2010-08-24
RU2404774C2 (ru) 2010-11-27
EP1883397B1 (en) 2009-12-16
RU2010129460A (ru) 2012-01-27
ZA200710903B (en) 2008-12-31
EP1883397A2 (en) 2008-02-06
CY1110610T1 (el) 2015-04-29
CA2607098C (en) 2012-04-10
BRPI0610187B1 (pt) 2020-03-03
CA2607098A1 (en) 2006-11-23
JP4219399B2 (ja) 2009-02-04
WO2006123285A3 (en) 2007-07-05
BRPI0610187A2 (pt) 2010-06-01
AU2006248593B2 (en) 2011-03-17
CN101175484B (zh) 2012-02-01
ES2336943T3 (es) 2010-04-19
KR20080014002A (ko) 2008-02-13
DK1883397T3 (da) 2010-04-06
NO20076325L (no) 2008-02-04
SI1883397T1 (sl) 2010-04-30
CN101175484A (zh) 2008-05-07

Similar Documents

Publication Publication Date Title
BRPI0610187B8 (pt) tablete dispersável ou um solvato ou sal farmaceuticamente aceitável do mesmo, e excipientes farmaceuticamente aceitáveis, processo para a preparação dos mesmos, e uso de composto ou de um sal ou solvato farmaceuticamente aceitável do mesmo
MX2008012576A (es) Pirimidinas 5-amido sustituidas inhibidoras del virus de inmunodeficiencia humana.
UA114411C2 (uk) ТАБЛЕТКА, ЩО МІСТИТЬ 7-[4-(4-БЕНЗО[b]ТІОФЕН-4-ІЛ-ПІПЕРАЗИН-1-ІЛ)БУТОКСИ]-1H-ХІНОЛІН-2-ОН АБО ЙОГО СІЛЬ
MA30725B1 (fr) Administration d'inhibiteurs de la dipeptidyl peptidase
MA29799B1 (fr) Administration d'inhibiteurs de dipeptidyl peptidase
CL2007002836A1 (es) Compuestos derivados de 1,3,5-triazina o pirimidina, inhibidores de quinasa; composicion farmaceutica; y uso para tratar una enfermedad mediada por quinasa, tal como cancer.
AR112118A2 (es) Inhibidores de pi-3 quinasa
DK2004641T3 (da) HIV-inhiberende 5-(hydroxymethylen og aminomethylen) substituerede pyrimidiner
CL2004000930A1 (es) Compuesto derivado de dihidroquinazolina de formula definida, util para el tratamiento y/o profilaxis de infecciones virales; composicion farmaceutica que comprende al compuesto y uso del compuesto en la preparacion de medicamentos.
CL2011002300A1 (es) Compuestos derivados de 2,4-diamiropirimidinas 5-sustitudas inhibidoras de quinasa ptk2; preparaciones farmaceuticas; y su uso para el tratamiento y/o la prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes.
NZ594385A (en) Aminopyrimidines useful as kinase inhibitors
CL2007001734A1 (es) Compuestos derivados de imidazol condensados con heterociclos nitrogenados; composicion farmaceutica; y uso para tratar o prevenir la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras.
CR8102A (es) Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa
TW200744602A (en) Administration of dipeptidyl peptidase inhibitors
ATE508126T1 (de) Als kinaseinhibitoren geeignete aminopyrimidine
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
UA92349C2 (ru) Полиморфы этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1н-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты
CL2011001215A1 (es) Compuestos derivados de pirimidina, inhibidores de tirosina quinasa; composiciones farmaceuticas que los comprenden; y su uso en el tratamiento y/o prevencion de cancer, enfermedades inflamatorias y enfermedades autoinmunes.
UA101313C2 (uk) Щотижневе введення інгібіторів дипептидилпептидази
CL2007001826A1 (es) Compuestos derivados de 2-(amino-sustituido)-benzotiazol-sulfonamida, inhibidores de proteasa, en particular, inhibidores de proteasa de vih; composicion farmaceutica; y uso para tratar o combatir una infeccion o enfermedad asociada con la infeccion de un retrovirus resistente a multiples farmacos.
WO2006065820A3 (en) Pyrimidine inhibitors of erk protein kinase and uses therof
AR031679A1 (es) Una composicion farmaceutica
MA39175A1 (fr) Capsule comprend 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-(6-(4-(4-ethyl-piperazin-1-yl)-phenylamino)-pyrimidin-4-yl)-1-methyl-uree, liant et desintegrant, pour le traitement des maladies proliferatives
ECSP077845A (es) Composiciones y sales dermatológicas para el tratamiento de enfermedades dermatológicas
WO2008020314A3 (en) Statin stabilizing dosage formulations

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/03/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/05/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF